Kim A Papp has received grant funding and/or honoraria from AbbVie, Akros, Amgen, Anacor, Arcutis, Avillion, Bausch Health/Valeant, Boehringer Ingelheim, BMS, Can-Fite Biopharma, Celgene, Celltrion, Coherus, Dermavant, Dermira, Dice Pharmaceuticals, Dow Pharma, Eli Lilly, Evelo, Galderma, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Meiji Seika Pharma, Merck, Mitsubishi Pharma, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharma, Takeda, UCB, vTv Therapeutics, and Xencor. Ron Vender has consulted, spoken for, or received grant funding and/or honoraria from AbbVie, Actelion, Amgen, Arcutis, Bausch-Health, Boehringer Ingelheim, BMS, Celgene, Centocor, Cipher, Demira, Dermavant, Eli Lily, Galderma, GSK, Innovaderm, Janssen, Kabi-Care, Leo, Meiji, Merck, Novartis, Palladin, Pfizer, Regeneron, Sandoz, Sun Pharma, Takeda, UCB, and Viatris-Mylan. Kerri Purdy has consulted for, spoken for, or received honoraria from Abbvie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, BMS, Eli Lilly, Galderma, Incyte Biosciences, Janssen, Leo, Novartis, Pfizer, Recordati, Sanofi, Sun Pharma, and UCB. Fiona Lovegrove has consulted, spoken for, or received grant funding and/or honoraria from AbbVie, Amgen, Arcutis, Bausch-Health/Valeant, Boehringer Ingelheim, BMS, Celgene, Cipher, Eli Lilly, Galderma, GSK, Incyte, Janssen, Leo, Novartis, Pfizer, Sandoz, Sanofi-Aventis/Genzyme, Sun Pharma, and UCB. Irina Oroz has consulted, spoken for, and/or received honoraria from AbbVie, Pfizer, UCB, Novartis, Janssen, Lilly, Galderma, Bausch, Arcutis, Leo, Sun Pharma, Johnson & Johnson, L’Oreal Canada, and Sanofi. Parbeer Grewal has consulted, spoken for, or received grant funding and/or honoraria from AbbVie, Amgen, Anacor, Arcutis, Arena Pharmaceuticals, Avillion, Bausch Health/Valeant, Boehringer Ingelheim, BMS, Celgene, Cipher, Dermavant, Dermira, Eli Lilly, Galderma, GSK, Incyte, Innovaderm, Johnson & Johnson/Janssen, Leo Pharma, Med Plan, Meiji Seika Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharmaceuticals, Takeda, UCB, Vitae. Perla Lansang has consulted, spoken for, or received honoraria from AbbVie, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galderma, Incyte, Janssen, Leo, Novartis, Pfizer, Regeneron, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharma, and UCB. Laura Park-Wyllie, Nastaran Abbarin, and Ya-Wen Yang are employees of Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson and may own stock/stock options in Johnson & Johnson. Becky Hooper, Sandra Vigelis, and Tim Disher are employees of EVERSANA. EVERSANA consults for various pharmaceutical and medical device companies and was contracted to support this work. Richard G Langley has received grant funding as an investigator and/or honoraria from AbbVie, Amgen, Astellas Pharma, Boehringer Ingelheim, Celgene, Centocor Ortho, Eli Lilly, Genentech, Isotechnika Pharma, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Sun Pharma, and UCB. The affiliation of two authors (Nastaran Abbarin and Tim Disher) has changed since the time of completion of this manuscript. At the time of publication, Nastaran Abbarin is affiliated with Novartis Pharmaceuticals Canada Inc., Toronto, ON, Canada, and Tim Disher is affiliated with Dalhousie University, Halifax, NS, Canada.

This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.